Alto Neuroscience (NYSE:ANRO) Trading 9.8% Higher – Should You Buy?

Alto Neuroscience, Inc. (NYSE:ANRO) shares were up 9.8% during trading on Monday . The stock traded as high as $16.78 and last traded at $16.7050. Approximately 64,608 shares changed hands during mid-day trading, a decline of 67% from the average daily volume of 197,205 shares. The stock had previously closed at $15.22.

Analysts Set New Price Targets

ANRO has been the subject of a number of analyst reports. BTIG Research began coverage on Alto Neuroscience in a research report on Monday, November 17th. They set a “buy” rating and a $27.00 price target for the company. Jefferies Financial Group upped their price objective on shares of Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 12th. HC Wainwright raised their target price on shares of Alto Neuroscience from $10.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Finally, Wall Street Zen raised Alto Neuroscience from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $26.33.

Alto Neuroscience Stock Up 10.4%

The stock has a market capitalization of $522.13 million, a P/E ratio of -7.34 and a beta of 2.79. The company has a debt-to-equity ratio of 0.20, a current ratio of 15.42 and a quick ratio of 15.42. The stock’s fifty day moving average is $16.43 and its two-hundred day moving average is $10.24.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.14. As a group, research analysts predict that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

A number of institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC lifted its stake in Alto Neuroscience by 20.8% during the fourth quarter. Geode Capital Management LLC now owns 287,435 shares of the company’s stock valued at $5,118,000 after buying an additional 49,535 shares in the last quarter. AlphaCore Capital LLC lifted its position in shares of Alto Neuroscience by 100.0% in the 4th quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $356,000 after acquiring an additional 10,000 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in Alto Neuroscience by 14,567.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock worth $3,786,000 after purchasing an additional 211,222 shares during the period. Torren Management LLC purchased a new position in Alto Neuroscience during the 4th quarter worth approximately $62,000. Finally, Armistice Capital LLC lifted its holdings in shares of Alto Neuroscience by 0.7% in the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock valued at $6,577,000 after purchasing an additional 12,000 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.